Epidemiology of Infections in Pediatric Cancer Patients
NCT00934115 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2009-07-16
Summary
Infections are common causes of morbidity and mortality in pediatric cancer patients. Today, there are limited data on the incidence, distribution of specific infections, causative agents and risk factors for severe infections in this population. Moreover, little data exist on the epidemiology of infections among pediatric patients with solid tumors.
The objectives of the present study are to define the incidence, categories of infections by organ systems, etiologic agents and risk factors for infections in different pediatric malignancies. The results of this study will help the investigators to better understand the epidemiology of infections in the different types of pediatric malignancies, enable the investigators to identify high risk patients, and design a better approach to empiric treatment of these patients.
A prospective, multi-center study, conducted in 5 pediatric hematology-oncology units across Israel (Rambam Medical Center, Haemek Medical Center, Schneider Children's Medical Center, Hadassah Medical Center, Soroka Medical Center). All children aged 0-18 years of age, newly diagnosed with cancer and admitted to day care or inpatient departments with fever of \>38.0 C will be included in the study. Demographic, clinical and microbiological figures will be collected in each center by a research assistant supervised by the infectious disease specialist. Data will be collected according to a pre-defined Patient Data Form and entered into an electronic data base that will be analyzed accordingly. In each event of febrile episode during chemotherapy, the following data will be collected by a research assistant using a patient data form and computerized software:
* Demographic data: age, gender, ethnicity.
* Clinical data: Underlying disease, immunizations, prophylactic antibiotics, presence of central venous catheter, intensity of chemotherapy, duration of fever, duration and severity of neutropenia, diagnosis of present event.
* Imaging data
* Microbiological data
* Outcome
The statistical analysis will be performed by an epidemiologist and statistician using the SPSS 12.0 software.
Conditions
Sponsors & Collaborators
-
Rabin Medical Center
lead OTHER
Eligibility
- Max Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-31
More Related Trials
-
Role of Children in Transmission of COVID-19 to Immunocompromised Patients
NCT04407546 ·Status: TERMINATED
-
SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia
NCT02324231 ·Status: COMPLETED ·Phase: NA
-
Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
NCT02509234 ·Status: UNKNOWN
-
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
NCT03458728 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
NCT01184274 ·Status: COMPLETED ·Phase: PHASE1
-
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
NCT05774990 ·Status: COMPLETED
-
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
NCT04478292 ·Status: RECRUITING ·Phase: PHASE3
-
Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy
NCT07240207 ·Status: RECRUITING
-
Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
NCT02675166 ·Status: COMPLETED
-
Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors
NCT00607984 ·Status: UNKNOWN ·Phase: NA
-
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
NCT00148993 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
NCT03245450 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia
NCT00022035 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
NCT02963389 ·Status: COMPLETED ·Phase: PHASE1
-
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
NCT00334854 ·Status: UNKNOWN ·Phase: PHASE3
-
Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma
NCT04055558 ·Status: UNKNOWN
-
Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia
NCT01688752 ·Status: WITHDRAWN
-
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
NCT00003801 ·Status: COMPLETED ·Phase: NA
-
Oxaliplatin for Children With Solid Tumors
NCT01558453 ·Status: UNKNOWN ·Phase: PHASE2
-
Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids
NCT04593745 ·Status: UNKNOWN ·Phase: NA
-
Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]
NCT03686566 ·Status: COMPLETED
-
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
NCT04327037 ·Status: COMPLETED ·Phase: PHASE1
-
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595 ·Status: RECRUITING ·Phase: PHASE1
-
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
NCT01683149 ·Status: COMPLETED ·Phase: PHASE1